Antagonist-agonist combinations as therapies for heroin addiction: Back to the future?

Journal of Psychopharmacology

Volumn 24, Issue 2, 2010, Pages 141-145

  Nutt, David J ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Agonist; Antagonist; Buprenorphine; Heroin; Methadone; Naloxone; Opioids

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; METHADONE; MU OPIATE RECEPTOR; NALMEFENE; NALOXONE; NALTREXONE; PENTAZOCINE;

DRUG MISUSE; HEROIN DEPENDENCE; HUMAN; MENTAL DISEASE; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; REVIEW;

DRUG THERAPY, COMBINATION; HEROIN DEPENDENCE; HUMANS; NARCOTIC ANTAGONISTS; NARCOTICS; RECEPTORS, OPIOID, MU;

EID: 76649089652     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881109356129     Document Type: Review

References (32)

1. Alho H., Sinclair D., Vuori E., Holopainen A. (2007) Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depen 88: 75-78.
2. Bell J., Shanahan M., Mutch C., et al. (2007) A randomized trial of effectiveness and cost-effectiveness of observed versus unobserved administration of buprenorphine-naloxone for heroin dependence. Addiction 102: 1899-1907.
3. Chindalore VL, Craven RA, Yu KP, Butera PG, Burns LH, Friedmann N. (2005) Adding ultralow-dose naltrexone to oxycodone enhances and prolongs analgesia: a randomized, controlled trial of Oxytrex. J Pain 6: 392-399.
4. Clark HW (2003) Office-based practice and opioid-use disorders. N Engl J Med 349: 928-930.
5. Comer SD, Burke TF, Lewis JW, Woods JH (1992) Clocinnamox: a novel, systemically-active, irreversible opioid antagonist. J Pharmacol Exp Ther 262: 1051-1056.
6. Comer SD, Sullivan MA, Yu E., et al. (2006) Injectable, sustained release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry 63: 210-218.
7. Correia CJ, Walsh SL, Bigelow GE, Strain EC (2006) Effects associated with double blind omission of buprenorphine/naloxone over a 98-h period. Psychopharmacology (Berl) 189: 297-306.
8. Fiellin DA, Pantalon MV, Chawarski MC, et al. (2006) Counselling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N Engl J Med 355: 365-374.
9. Fudala PJ, Bridge TP, Herbert S., et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med 349: 949-958.
10. Gerra G., Fantoma A., Zaimovic A. (2006) Naltrexone and buprenorphine combination in the treatment of opioid dependence. J Psychopharmacol 20: 806-814.
11. Gorlick DA, Fiellin DA, Moore BA, Schottenfeld RS (2008) Counseling plus buprenorphine-naloxone for opioid dependence. N Engl J Med 355: 1736-1737.
12. Helm SII, Trescot AM, Colson J., Sehgal N., Silverman S. (2008) Opioid antagonists, partial agonists, and agonists/antagonists: the role of office- based detoxification. Pain Physician 11: 225-235.
13. Hulse GK, Tait RJ, Comer SD, Sullivan MA, Jacobs IG, Arnold-Reed D. (2005) Reducing hospital presentations for opioid overdose in patients treated with sustained release naltrexone implants. Drug Alcohol Depend 79: 351-357.
14. Husbands SM, Sadd J., Broadbear JH, et al. (1998) 3-Alkyl ethers of clocinnamox: delayed long-term mu-antagonists with variable mu efficacy. J Med Chem 41: 3493-3498.
15. Krystal JH, Walker MW, Heninger GR (1989) Intermittent naloxone attenuates the development of physical dependence on methadone in rhesus monkeys. Eur J Pharmacol 160: 331-338.
16. Law F., Daglish MRC, Myles JS, Nutt DJ (2004) The clinical use of buprenorphine in opiate addiction: evidence and practice. Acta Neuropsychiatrica 16: 246-274.
17. Ling W., Amass L., Shoptaw S., et al. (2005) A multi-center randomized trial of buprenorphine- naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction 100: 1090-1100.
18. Legros J., Khalili-Varasteh H., Margetts G. (1984) Pharmacological study of pentazocine-naloxone combination: interest as a potentially non abusable oral form of pentazocine. Arch Int Pharmacodyn Ther 271: 11-21.
19. Martin WR, Jasinski DR, Mansky PA (1973) Naltrexone, an antagonist for the treatment of heroin dependence. Effects in man. Arch Gen Psychiatry 28 (6). 784-791. PMID: 4707988 [PubMedindexed for MEDLINE].
20. Melichar JK, Myles JS, Eap CB, Nutt DJ (2003 a) Using saccadic eye movements as objective measures of tolerance in methadone dependent individuals during the hydromorphone challenge test. Addict Biol 8: 59-66.
21. Melichar JK, Nutt DJ, Malizia AL (2003 b) Naloxone displacement at opioid receptor sites measured in vivo in the human brain. Eur J Pharmacol 459: 217-219.
22. Melichar JK, Hume SP, Williams TM, et al. (2005) Using [11C]Diprenorphine to image opioid receptor occupancy by methadone in opioid addiction: clinical and preclinical studies. J Pharm Exp Ther 312: 309-315.
23. Milroy C., Forrest A. (2000) Methadone deaths: a toxicological analysis. J Clin Pathol 53: 277-281.
24. Mintzer IL, Eisenberg M., Terra M., MacVane C., Himmelstein DU, Woolhandler S. (2007) Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings. Ann Fam Med 5: 146-150 (Available at: www.pubmedcentral. nih.gov/picrender.fcgi?artid=1838690 & blobtype=pdf).
25. Nutt DJ (1997) Receptor pharmacology of buprenorphine. Buprenorphine-a substitution agent for the treatment of opioid addiction: a UK perspective. Res Clin Forums 9-15.
26. Nutt JG, Jasinski DR (1974) Methadone-naloxone mixtures for use in methadone maintenance programs. I. An evaluation in man of their pharmacological feasibility. II. Demonstration of acute physical dependence. Clin Pharmacol Ther. Feb; 15 (2). 156-166.
27. Pettinati HM, OBrien CP, Rabinowitz AR, et al. (2006) The status of naltrexone in the treatment of alcohol dependence: Specific effects on heavy drinking. J Clin Psychopharmacol 26: 610-625.
28. Poklis A. (1984) Decline in abuse of pentazocine/tripelennamine (Ts and Blues) associated with the addition of naloxone to pentazocine tablets. Drug Alcohol Depend 14: 135-140.
29. Ray LA, Hutchison KE (2007) Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response. a double-blind placebo-controlled study. Arch Gen Psychiatry 64: 1069-1077.
30. Reed DA, Schnoll SH (1986) Abuse of pentazocine-naloxone combination. JAMA 256: 2562-2564.
31. Srisurapanont M., Jarusuraisin N. (2005) Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev CD001867.
32. Stoller KB, Bigelow GE, Walsh SL, Strain EC (2001) Effects of buprenorphine/naloxone in opioid-dependent humans. Psychopharmacology 154: 230-242.